of neurology live® The team spoke with hundreds of experts in the field of neurology, culminating in hundreds of hours of interview clips posted over the course of the year. Staff spoke with everyone involved in the clinical care delivery process, including neurologists, investigators, advanced care providers, physical therapists, advocates, patients, pharmacists, and industry experts.
These conversations were conducted virtually and face-to-face with individuals from all over the world. The team he attended more than 10 medical society annual meetings, each time sitting with experts in the field to learn more about the conversations that facilitate care and the challenges being overcome.
This year, we learned from researchers in the field of movement disorders about the latest pharmaceutical efforts to perfect levodopa, the gold standard treatment for Parkinson’s disease. Highlights from the 1st Advanced Therapeutics in Movement and Related Disorders (ATMRD) Conference. advances in biomarker science; lingering gaps in care for movement disorders, especially women, and more.
Here are our most viewed expert interviews. neurology live® this year. Click the button to see more conversations with these experts.
1. RISE-PD study of IPX-203 in Parkinson’s disease: Robert A. Hauser, MD, MBA
The Director of the Center for Parkinson’s Disease and Movement Disorders at the University of South Florida elaborated on the data presented at AAN 2022 and the potential of IPX-203 in Parkinson’s disease. Watch time: 3 minutes
“[With] It’s a key outcome measure for good ON-time increases, and many people look at it and say, “Well, 0.53 hours is a 30-minute increase in ON-time, which isn’t much per day.” increase. However, the patient must remember that her IPX-203 was administered three times a day, whereas IR CD-LD he was administered an average of five times a day. ”
2. Advanced Therapeutics Highlights at Movement and Related Disorders Conference: Jean Hubble, MD
A semi-retired neurologist and PMD Alliance consultant, she shared lessons learned from the 2022 ATMRD conference in Washington, DC and advice for young clinicians entering the field. Watch time: 3 minutes
“It is very exciting to be in this conference room with APP, Fellows and Senior Residents. I see medicine and the care of these people in a way that is very different from my role in the world.”
3. Interdisciplinary care and hot topics in movement disorders: Jill Farmer, DO, MPH
The Director of the Parkinson’s Disease and Movement Disorders Program at the Global Neuroscience Institute spoke about the importance of a multidisciplinary approach to movement disorders and a hot topic of conversation at ATRD. Watch time: 2 minutes
“No one can be an expert in everything. You will have a doctor or an APP [as] Someone taking over a clinical role in partnership with someone trying to address social issues, such as a social worker or therapist, and someone trying to take charge of rehabilitation strategies.
4. The future of tears as a biomarker for neurodegenerative disease: Mark Lew, MD
The director of the Movement Disorders Division at the USC Keck School of Medicine provided insight into next steps in how tears can be expanded as a valuable biomarker for neurodegenerative diseases. Watching time: 4 minutes
“It is very important that we have biomarkers to distinguish between Parkinson’s disease and atypical syndromes in both synucleinopathy and tauopathy. [multiple system atrophy]Lewy body disease, [progressive supranuclear palsy], and corticobasal syndrome as well. ”
5. Knowledge gaps in treating women with Parkinson’s disease: Indu Subramanian, MD
Director of VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers and Clinical Professor of Neurology at UCLA Discussed Lack of More Focused and Specific Approaches to Care for Women with Parkinson’s Disease . Watching time: 6 minutes
“When you think about the ER doctors who see patients in emergency care, and who may be the only point of care, they think people like me might have Parkinson’s disease. I don’t think…it’s very classic.The perception of the disease and the way society thinks about who has Parkinson’s really has to change.”
6. Future Plans and Goals of Prime PD: Konstantin Karmazin, MD
The chief medical officer of Prime PD, a new digital wellness studio for people with Parkinson’s disease, elaborated on the platform’s future endeavors. Watching time: 4 minutes
“In general, exercise is good for everyone, and the nervous system in particular responds really well. will be very open to [multiple sclerosis] For example, an exercise fitness program. ”
7. The need to address the non-motor symptoms of Parkinson’s disease: Neal Hermanowicz, MD
A neurologist at Christus St. Vincent Health System provided insight into the desperate need for new treatments for both motor and non-motor symptoms of Parkinson’s disease. Watch time: 3 minutes
“Another major symptom I hear all the time from my patients is fatigue. We don’t really know where it’s coming from. What do we do about it?”
8. Recognition of Botulinum Toxin in Movement Disorders: Laxman Bahroo, DO
An assistant professor of neurology and co-director of the Neurology Residency Program at MedStar Georgetown University Hospital, he shared his thoughts on the 2022 ATMRD conference and a step towards increasing patient awareness of treatment options. Watch time: 3 minutes
“The botulinum toxin has been around for 30 years and it’s still new. That’s the amazing thing about it. say. This is my first time getting an injection. I hate to say this has been around for his 30 years, but awareness of botulinum toxin continues to grow. ”
9. Exercise, Virtual Reality, and Parkinson’s Prodromal Exposure: Dr. Jay Alberts
The Edward F. and Barbara A. Bell Endowed Chair at the Cleveland Clinic detailed how a new virtual reality tool can elucidate the prodromal symptoms in people with Parkinson’s disease. Watch time: 3 minutes
“What we’re trying to do now is collect data that will eventually red or yellow flag me to go to a neurologist because my vitals seem a little off. These are my It’s something we definitely want to do.”
10. PreciseDx AI morphology feature arrays for detecting Parkinson’s disease pathology: John F. Crary, MD, PhD; Gerald Fernandez, M.D.
A neuropathologist at Mount Sinai and chief scientific officer of the Precise Dx pairing shared background information on artificial intelligence’s ability to improve Parkinson’s disease diagnosis from peripheral tissue biopsies. Watching time: 9 minutes
“One of the big problems [identifying pathology in peripheral tissue] The pathology is very elusive. Screening these slides to find these peripheral axons is very time consuming and difficult. I was trained to do it with the other neuropathologists on the project, and I was always thinking, “There must be a better way to do this.” If you can do that, that’s great. That’s how this project was born. ”
